|
1
|
Siegel RL, Wagle NS, Cercek A, Smith RA
and Jemal A: Colorectal cancer statistics, 2023. CA Cancer J Clin.
73:233–254. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cervantes A, Adam R, Roselló S, Arnold D,
Normanno N, Taïeb J, Seligmann J, De Baere T, Osterlund P, Yoshino
T, et al: Metastatic colorectal cancer: ESMO clinical practice
guideline for diagnosis, treatment and follow-up. Ann Oncol.
34:10–32. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ciombor KK and Bekaii-Saab T: A
comprehensive review of sequencing and combination strategies of
targeted agents in metastatic colorectal cancer. Oncologist.
23:25–34. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Goel G: Evolution of regorafenib from
bench to bedside in colorectal cancer: Is it an attractive option
or merely a ‘me too’ drug? Cancer Manag Res. 10:425–437. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vogel A, Hofheinz RD, Kubicka S and Arnold
D: Treatment decisions in metastatic colorectal cancer-beyond first
and second line combination therapies. Cancer Treat Rev. 59:54–60.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Morris VK, Kennedy EB, Baxter NN, Benson
AB III, Cercek A, Cho M, Ciombor KK, Cremolini C, Davis A, Deming
DA, et al: Treatment of metastatic colorectal cancer: ASCO
guideline. J Clin Oncol. 41:678–700. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yaghoubi N, Soltani A, Ghazvini K,
Hassanian SM and Hashemy SI: PD-1/PD-L1 blockade as a novel
treatment for colorectal cancer. Biomed Pharmacother. 110:312–318.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
André T, Shiu KK, Kim TW, Jensen BV,
Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs
P, et al: Pembrolizumab in microsatellite-instability-high advanced
colorectal cancer. N Engl J Med. 383:2207–2218. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sahin IH, Akce M, Alese O, Shaib W,
Lesinski GB, El-Rayes B and Wu C: Immune checkpoint inhibitors for
the treatment of MSI-H/MMR-D colorectal cancer and a perspective on
resistance mechanisms. Br J Cancer. 121:809–818. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Borelli B, Antoniotti C, Carullo M,
Germani MM, Conca V and Masi G: Immune-checkpoint inhibitors (ICIs)
in metastatic colorectal cancer (mCRC) patients beyond
microsatellite instability. Cancers (Basel). 14:49742022.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
André T, Lonardi S, Wong KYM, Lenz HJ,
Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill
A, et al: Nivolumab plus low-dose ipilimumab in previously treated
patients with microsatellite instability-high/mismatch
repair-deficient metastatic colorectal cancer: 4-Year follow-up
from CheckMate 142. Ann Oncol. 33:1052–1060. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Eng C, Kim TW, Bendell J, Argilés G,
Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal
NH, et al: Atezolizumab with or without cobimetinib versus
regorafenib in previously treated metastatic colorectal cancer
(IMblaze370): A multicentre, open-label, phase 3, andomized,
controlled trial. Lancet Oncol. 20:849–861. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao S, Ren S, Jiang T, Zhu B, Li X, Zhao
C, Jia Y, Shi J, Zhang L, Liu X, et al: Low-dose apatinib optimizes
tumor microenvironment and potentiates antitumor effect of
PD-1/PD-L1 blockade in lung cancer. Cancer Immunol Res. 7:630–643.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Konecny GE: Inhibition of PD-1 and VEGF in
microsatellite-stable endometrial cancer. Lancet Oncol. 20:612–614.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu RY, Kong PF, Xia LP, Huang Y, Li ZL,
Tang YY, Chen YH, Li X, Senthilkumar R, Zhang HL, et al:
Regorafenib promotes antitumor immunity via inhibiting PD-L1 and
IDO1 expression in melanoma. Clin Cancer Res. 25:4530–4541. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fukuoka S, Hara H, Takahashi N, Kojima T,
Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, et
al: Regorafenib plus nivolumab in patients with advanced gastric or
colorectal cancer: An open-label, dose-escalation, and
dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol.
38:2053–2061. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cousin S, Cantarel C, Guegan JP,
Gomez-Roca C, Metges JP, Adenis A, Pernot S, Bellera C, Kind M,
Auzanneau C, et al: Regorafenib-avelumab combination in patients
with microsatellite stable colorectal cancer (REGOMUNE): A
single-arm, open-label, phase II trial. Clin Cancer Res.
27:2139–2147. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang W, Zhang Z, Lou S, Li D, Ma Z and
Xue L: Efficacy, safety and predictors of combined fruquintinib
with programmed death-1 inhibitors for advanced
microsatellite-stable colorectal cancer: A retrospective study.
Front Oncol. 12:9293422022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stang A: Critical evaluation of the
Newcastle-Ottawa scale for the assessment of the quality of
nonrandomized studies in meta-analyses. Eur J Epidemiol.
25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen B, Zhao H, Huang J, Lv H, Xu W, Nie
C, Wang J, Zhao J, He Y, Wang S and Chen X: Efficacy of regorafenib
combined with PD-1 inhibitors in elderly patients with advanced
metastatic colorectal cancer. BMC Geriatr. 22:9872022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang C, Chevalier D, Saluja J, Sandhu J,
Lau C and Fakih M: Regorafenib and nivolumab or pembrolizumab
combination and circulating tumor DNA response assessment in
refractory microsatellite stable colorectal cancer. Oncologist.
25:e1188–e1194. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He WZ, Wang L, Yin CX, Yi JH, Jin YN,
Jiang C, Guo GF and Xia LP: Regorafenib with or without a
programmed cell death protein 1 antibody as third-line treatment
for microsatellite stable metastatic colorectal cancer. Cancer Med.
12:6488–6498. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim RD, Kovari BP, Martinez M, Xie H,
Sahin IH, Mehta R, Strosberg J, Imanirad I, Ghayouri M, Kim YC and
Kim DW: A phase I/Ib study of regorafenib and nivolumab in mismatch
repair proficient advanced refractory colorectal cancer. Eur J
Cancer. 169:93–102. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li J, Cong L, Liu J, Peng L, Wang J, Feng
A, Yue J, Li L and Wang X and Wang X: The efficacy and safety of
regorafenib in combination with anti-PD-1 antibody in refractory
microsatellite stable metastatic colorectal cancer: A retrospective
study. Front Oncol. 10:5941252020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ma S, Chen R, Duan L, Li C, Yang T, Wang J
and Zhao D: Efficacy and safety of toripalimab with fruquintinib in
the third-line treatment of refractory advanced metastatic
colorectal cancer: Results of a single-arm, single-center,
prospective, phase II clinical study. J Gastrointest Oncol.
14:1052–1063. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ren C, Mai ZJ, Jin Y, He MM, Wang ZQ, Luo
HY, Zhang DS, Wu CY, Wang F and Xu RH: Anti-PD-1 antibody SHR-1210
plus apatinib for metastatic colorectal cancer: A prospective,
single-arm, open-label, phase II trial. Am J Cancer Res.
10:2946–2954. 2020.PubMed/NCBI
|
|
28
|
Sun L, Huang S, Li D, Mao Y, Wang Y and Wu
J: Efficacy and safety of fruquintinib plus PD-1 inhibitors versus
regorafenib plus PD-1 inhibitors in refractory microsatellite
stable metastatic colorectal cancer. Front Oncol. 11:7548812021.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu YJ, Zhang P, Hu JL, Liang H, Zhu YY,
Cui Y, Niu P, Xu M and Liu MY: Regorafenib combined with programmed
cell death-1 inhibitor against refractory colorectal cancer and the
platelet-to-lymphocyte ratio's prediction on effectiveness. World J
Gastrointest Oncol. 14:920–934. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang K, Han L, Wu S, Qu X, Li Q, Zhao C,
Zhou J, Jin X, Wang Y, Yan D, et al: Real-world outcomes of
regorafenib combined with immune checkpoint inhibitors in patients
with advanced or metastatic microsatellite stable colorectal
cancer: A multicenter study. Cancer Immunol Immunother.
71:1443–1451. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yu W, Tao Q, Zhang Y, Yi F and Feng L:
Efficacy and safety of regorafenib combined with toripalimab in the
third-line and beyond treatment of advanced colorectal cancer. J
Oncol. 2021:99599462021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA,
Atkins MB, Leming PD, et al: Five-year survival and correlates
among patients with advanced melanoma, renal cell carcinoma, or
non-small cell lung cancer treated with nivolumab. JAMA Oncol.
5:1411–1420. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Overman MJ, McDermott R, Leach JL, Lonardi
S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al:
Nivolumab in patients with metastatic DNA mismatch repair-deficient
or microsatellite instability-high colorectal cancer (CheckMate
142): An open-label, multicentre, phase 2 study. Lancet Oncol.
18:1182–1191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mlecnik B, Bindea G, Angell HK, Maby P,
Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M,
Fredriksen T, et al: Integrative analyses of colorectal cancer show
immunoscore is a stronger predictor of patient survival than
microsatellite instability. Immunity. 44:698–711. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lenz HJ, Van Cutsem E, Luisa Limon M, Wong
KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G,
Cardin DB, et al: First-line nivolumab plus low-dose ipilimumab for
microsatellite instability-high/mismatch repair-deficient
metastatic colorectal cancer: The phase II CheckMate 142 study. J
Clin Oncol. 40:161–170. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu Q, Wang Z, Luo Y and Xie X: Efficacy
and safety of immune checkpoint inhibitors in proficient mismatch
repair (pMMR)/non-microsatellite instability-high (non-MSI-H)
metastatic colorectal cancer: A study based on 39 cohorts
incorporating 1723 patients. BMC Immunol. 24:272023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang Y, Chen X, Dikov MM, Novitskiy SV,
Mosse CA, Yang L and Carbone DP: Distinct roles of VEGFR-1 and
VEGFR-2 in the aberrant hematopoiesis associated with elevated
levels of VEGF. Blood. 110:624–631. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wada J, Suzuki H, Fuchino R, Yamasaki A,
Nagai S, Yanai K, Koga K, Nakamura M, Tanaka M, Morisaki T and
Katano M: The contribution of vascular endothelial growth factor to
the induction of regulatory T-cells in malignant effusions.
Anticancer Res. 29:881–888. 2009.PubMed/NCBI
|
|
40
|
Loupakis F, Antonuzzo L, Bachet JB, Kuan
FC, Macarulla T, Pietrantonio F, Xu RH, Taniguchi H, Winder T, Yuki
S, et al: Practical considerations in the use of regorafenib in
metastatic colorectal cancer. Ther Adv Med Oncol.
12:17588359209568622020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen Z and Jiang L: The clinical
application of fruquintinib on colorectal cancer. Expert Rev Clin
Pharmacol. 12:713–721. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sun Q, Zhou J, Zhang Z, Guo M, Liang J,
Zhou F, Long J, Zhang W, Yin F, Cai H, et al: Discovery of
fruquintinib, a potent and highly selective small molecule
inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.
Cancer Biol Ther. 15:1635–1645. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gu Y, Wang J, Li K, Zhang L, Ren H, Guo L,
Sai Y, Zhang W and Su W: Preclinical pharmacokinetics and
disposition of a novel selective VEGFR inhibitor fruquintinib
(HMPL-013) and the prediction of its human pharmacokinetics. Cancer
Chemother Pharmacol. 74:95–115. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xu X, Yu Y, Liu M, Liang L and Liu T:
Efficacy and safety of regorafenib and fruquintinib as third-line
treatment for colorectal cancer: A narrative review. Transl Cancer
Res. 11:276–287. 2022. View Article : Google Scholar : PubMed/NCBI
|
